Cytovia: activating NK cells at the tumor site

After bolstering its management team with new hires from BMS and AGTC, Cytovia is leveraging its two NK cell platforms and at least 11 partnerships to enter the clinic next year with therapies targeting solid and liquid tumors. The Aventura, Fla.-based company also has its sights set on a public market debut late this year or early next.

Cytovia’s two complementary approaches comprise induced pluripotent stem cell-derived CAR NK cells and NK cell engager multifunctional antibodies...